Table 5 Prevalence of Lipid-lowering Medications in Clinic HTG Patients
| Â | Â | Upon Arrival* | Clinic Treatment* | Latest Visit** |
|---|---|---|---|---|
| Â | Â | n (%) | n (%) | n (%) |
Monotherapy: | Fibrate | 17 (17.9) | 54 (56.8) | 31 (36.9) |
| Â | Statin | 16 (16.8) | 1 (1.1) | 6 (7.1) |
| Â | Fish Oil | 1 (1.1) | 8 (8.4) | 3 (3.6) |
| Â | Niacin | 1 (1.1) | 0 | 2 (2.4) |
| Â | Resin | 1 (1.1) | 0 | 1 (1.2) |
Combination: | Fibrate/Statin | 4 (4.2) | 9 (9.5) | 11 (13.1) |
| Â | Fibrate/Niacin/Fish Oil | 1 (1.1) | 1 (1.1) | 1 (1.2) |
| Â | Fibrate/Fish Oil | 1 (1.1) | 16 (16.8) | 4 (4.8) |
| Â | Other | 0 | 2 (2.2) | 17 (20.2) |